First clinical trial of purified, irradiated malaria sporozoites in humans (Q38962844)

8 September 2017

First clinical trial of purified, irradiated malaria sporozoites in humans (English)

1 reference

8 September 2017

1 reference

Claudia A Daubenberger

series ordinal

1

1 reference

8 September 2017

1 January 2012

1 reference

Expert Review of Vaccines

8 September 2017

1 reference

8 September 2017

11

1 reference

8 September 2017

1

1 reference

8 September 2017

31-33

1 reference

Advances and challenges in malaria vaccine development

8 September 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Vaccines: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Caught in action: mechanistic insights into antibody-mediated inhibition of Plasmodium merozoite invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

The development of the RTS,S malaria vaccine candidate: challenges and lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Protection against a malaria challenge by sporozoite inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Targeting Plasmodium liver stages: better late than never

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Natural immunization against malaria: causal prophylaxis with antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Drug-resistant genotypes and multi-clonality in Plasmodium falciparum analysed by direct genome sequencing from peripheral blood of malaria patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

Clinical development of malaria vaccines: should earlier trials be done in malaria endemic countries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.161

21 January 2018

Identifiers

DOI

10.1586/ERV.11.161

1 reference

8 September 2017

1 reference

PubMed ID

22149705